263410-16-8

Basic information

• Product Name: tert-butyl (2-(2-aMinophenoxy)ethyl)carbaMate
• Synonyms: tert-butyl (2-(2-aMinophenoxy)ethyl)carbaMate
• CAS NO: 263410-16-8
• Molecular Formula: C₁₃H₂₀N₂O₃
• Molecular Weight: 252.3095
• Mol File: 263410-16-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 411.2±25.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• PKA: 12.11±0.46(Predicted)
• CAS DataBase Reference: tert-butyl (2-(2-aMinophenoxy)ethyl)carbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (2-(2-aMinophenoxy)ethyl)carbaMate(263410-16-8)
• EPA Substance Registry System: tert-butyl (2-(2-aMinophenoxy)ethyl)carbaMate(263410-16-8)

Safety Data

• Hazardous Substances Data: 263410-16-8(Hazardous Substances Data)

Usage

General Description

Tert-butyl (2-(2-aminophenoxy)ethyl)carbamate is a chemical compound that belongs to the carbamate group. It is derived from tert-butyl isocyanate and 2-(2-aminophenoxy) ethanol. tert-butyl (2-(2-aminophenoxy)ethyl)carbamate is used in the production of pesticides and insecticides due to its ability to act as a carbamate pesticide that inhibits the activity of acetylcholinesterase enzymes in target organisms. It is also used as a stabilizer in polymers and plastics to improve their thermal and UV resistance. However,

Upstream product

• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 88-75-5 2-hydroxynitrobenzene 
• 263410-15-7 tert-butyl (2-(2-nitrophenoxy)ethyl)carbamate 

Downstream Products

• 1430403-11-4 C₁₉H₂₇N₃O₆ 
• 1430403-13-6 C₁₈H₂₄N₆O₄S 
• 1430403-14-7 C₂₆H₂₈N₆O₄S 
• 1430402-87-1 C₂₁H₂₀N₆O₂S 

Relevant articles and documents

Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery

Glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), is an established prostate cancer marker and is considered a promising target for specific anticancer drug delivery. Low-molecular-weight inhibitors of GCPII are advantageous specific ligands for this purpose. However, they must be modified with a linker to enable connection of the ligand with an imaging molecule, anticancer drug, and/or nanocarrier. Here, we describe a structure-activity relationship (SAR) study of GCPII inhibitors with linkers suitable for imaging and drug delivery. Structure-assisted inhibitor design and targeting of a specific GCPII exosite resulted in a 7-fold improvement in Ki value compared to the parent structure. X-ray structural analysis of the inhibitor series led to the identification of several inhibitor binding modes. We also optimized the length of the inhibitor linker for effective attachment to a biotin-binding molecule and showed that the optimized inhibitor could be used to target nanoparticles to cells expressing GCPII.